Printer Friendly

SOMANETICS ANNOUNCES APPROVAL TO MARKET INVOS 3100 CEREBRAL OXIMETER IN JAPAN

 SOMANETICS ANNOUNCES APPROVAL TO MARKET INVOS 3100
 CEREBRAL OXIMETER IN JAPAN
 TROY, Mich., Oct. 29 /PRNewswire/ -- Somanetics Corporation (NASDAQ-NMS: SMTS) announced today that its INVOS(R) 3100 Cerebral Oximeter has been approved by the Japanese Ministry of Health and Welfare. Japan's approval is essentially equivalent to the U.S. Food and Drug Administration's clearance to market the INVOS 3100 Cerebral Oximeter domestically, announced in July.
 The approval was followed by an initial order for Somanetics' proprietary product by Sun Instruments Japan Company, Ltd., of Tokyo, Somanetics' Japanese distributor. "We demonstrated the Cerebral Oximeter at a clinical anesthesiology conference in Japan last week and the Somanetics exhibit was the busiest by far," said Yoh Chie Lu, president of Sun Instruments. "Many doctors in Japan are familiar with Somanetics' device and are anxious to get it in their hospitals."
 Somanetics' INVOS 3100 Cerebral Oximeter is the first product of its kind to monitor, noninvasively, directly and continuously, the oxygen saturation of the blood in portions of an adult's brain. It utilizes In Vivo Optical Spectroscopy (INVOS) technology which may be used to quantify various characteristics of human blood and tissue, by measuring low-intensity visible and near infrared light -- virtually eliminating the extraneous information around the brain caused by surrounding bone, muscle and other tissue. Because of the short period of time that the brain is able to survive without sufficient oxygen, immediate accurate information is of vital importance to medical personnel.
 Over the past year, Somanetics has established a global distribution network for the INVOS 3100 Cerebral Oximeter including sales and marketing representation in the U.S., Japan, Argentina, Australia and New Zealand, Canada, France, Italy, Korea, The Netherlands and the United Kingdom. The worldwide sales and specialty network is expected to continue to expand as the product is introduced to hospitals' operating rooms, emergency rooms, recovery rooms and intensive care units.
 Somanetics Corporation is headquartered in Troy and has 44 employees. The company develops, manufactures and markets computer- based medical diagnostic and monitoring equipment using INVOS technology.
 The company's Common Shares and Class B Warrants are publicly traded on the NASDAQ National Market System under the symbol SMTS and SMTSZ, respectively.
 -0- 10/29/92
 /CONTACT: Michael Ard, manager of Public Relations, Somanetics Corporation, 313-689-3050/
 (SMTS) CO: Somanetics Corporation ST: Michigan IN: MTC SU:


MI-KR -- DE009 -- 6441 10/29/92 09:32 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 29, 1992
Words:392
Previous Article:HILLHAVEN ANNOUNCES OFFERING OF $65,000,000 CONVERTIBLE SUBORDINATED DEBENTURES
Next Article:OHM CORPORATION IS AWARDED CONTRACT WORTH $50 MILLION
Topics:


Related Articles
SOMANETICS SIGNS AGREEMENTS WITH MEDICAL SPECIALTY DISTRIBUTORS IN JAPAN AND U.S.
SOMANETICS CORPORATION ANNOUNCES YEAR-END RESULTS
SOMANETICS ANNOUNCES CLEARANCE TO MARKET INVOS 3100 CEREBRAL OXIMETER
SOMANETICS CORPORATION ANNOUNCES FISCAL SECOND-QUARTER RESULTS
'OUTSIDE LOOKING IN' -- A WINDOW TO THE BRAIN
SOMANETICS CORPORATION SECURITIES WILL TRADE IN NASDAQ NATIONAL MARKET
SOMANETICS ANNOUNCES PATENT AWARD
SOMANETICS WINS LEADING EDGE TECHNOLOGIES AWARD
SOMANETICS CORPORATION ANNOUNCES YEAR-END RESULTS
CURTAIN OPENS ON SOMANETICS' WINDOW TO THE BRAIN WITH THE START OF INVOS 3100 CEREBRAL OXIMETER COMMERCIAL SHIPMENTS

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters